Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data ...

Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

A new study has made the case for synching your daily calories with your own circadian rhythm to improve glucose metabolism, ...

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

An oral melanocortin-4 receptor agonist conferred significant BMI reductions among adolescents and adults with hypothalamic ...

Rhythm Pharmaceuticals excels in rare genetic obesity treatments with innovative therapies, market potential, and growth opportunities. Learn more on RYTM stock here.

Rhythm Pharmaceuticals' experimental drug helped patients with a rare form of obesity caused by brain damage cut weight in a small study, the drugmaker said on Monday, sending its shares 24% higher in ...

Rhythm said results of the recent trial were also consistent with BMI reductions achieved with setmelanotide therapy in similar patient populations in past trials. Setmelanotide, an existing ...

Rhythm Pharmaceuticals, Inc. (RYTM) on Wednesday announced that its drug Bivamelagon achieved statistically significant and ...